DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2064
INDEX
Propidium, 241
PROPINE (epinephrine), 1787
Propionibacterium acnes, 1816–1817
Propionic acid derivatives, 987–989
classification of, 968t–969t
drug interactions with, 988
mechanism of action of, 987
structures of, 988f
therapeutic uses of, 987–988
Propionyl levocarnitine, 772
Propofol
in anesthesia, 540–542
formulations of, 538t
pharmacokinetics of, 1878t
pharmacological properties of, 538t,
544t
Propoxyphene
absorption, fate, and excretion of,
509
pharmacological actions, 509
structure of, 504f
therapeutic uses of, 510
tolerance and dependence, 509–510
toxicity, 509
Propranolol, 128t
absorption, fate, and excretion of,
320
adrenergic receptors and, 207t
antiarrhythmic use of, 828,
831–832, 836t
as antihypertensive agent, 774t,
778–779
cardioprotective effects of, 767
dosage of, 836t
electrophysiological actions of, 829t
pharmacokinetics of, 29, 836t, 1878t
polymorphisms and response to,
159t
structure of, 311f
therapeutic uses of, 320
N-propylajmaline, 159t
Propylene glycol, keratolytic effect of,
1829
Propylhexedrine, structure of, 279t
Propyliodone, 1153t
Prorenin, 722
activation of, 724f
angiotensin Ii-dependent and
angiotensin II-independent
actions of, 726f
Prorenin receptor, 725–726
PROSCAR (finasteride), 1841
PROSOM (estazolam), 466t
Prostacyclin (PGI 2
), 937
catabolism of, 942
effects on platelets, 949
Prostacyclin (PGI 2
) (Cont.):
and gastric acid secretion, 950
and gastrointestinal muscle, 950
in inflammation, 960
and intestinal secretions, 950
pain and, 961
Prostacyclin synthase, 939
Prostaglandin analogs, 1314–1315
for glaucoma, 1787
Prostaglandin D, 939
Prostaglandin D 2
, 939
catabolism of, 942
in inflammation, 960
Prostaglandin E, 939
and gastric/intestinal secretions, 950
and gastrointestinal muscle, 950
and uterus, 950
Prostaglandin E 1
, history of, 937
Prostaglandin E 2
, 939
for cervical ripening, 952
in inflammation, 960
pain and, 961
Prostaglandin F
and gastrointestinal muscle, 950
and tracheal muscle, 950
and uterus, 950
Prostaglandin F 1α
, history of, 937
Prostaglandin F 2α
, pain and, 961
Prostaglandin H 2
, 939
metabolism, inhibition of, 942
Prostaglandin(s) (PG), 926, 927f
biosynthesis of, inhibition of,
NSAIDs and, 963–965
cardiovascular effects of, 946–947
and cervical ripening, 1849–1850
for claudication, 772
endogenous, functions of, 946–948
history of, 937
in inflammation, 960–961
and pain, 951
PGE 1
, therapeutic uses of, for
impotence, 952
as pruritogens, 1815
pulmonary effects of, 947
receptors, 944t
renal effects of, 947–948, 950
and vasopressin secretion, 704
Prostaglandin (PG) receptors,
942–944, 944t
Prostanoid receptor(s), 945f
cell signaling pathways, 944–946
expression, 944–946
signaling pathways, 945f
Prostanoids
degradation of, 943f
in inflammation, 960–961
Prostate
ABC transporters in, 106t
alpha adrenergic receptors in, 203t
Prostate cancer
drugs for, 1668t–1670t
hormone therapy in, 1763–1767
Prostatic hyperplasia, benign, alphaadrenergic
receptor
antagonists for, 308
PROSTIN E2 (dinoporstone), 1837
PROSTIN VR PEDIATRIC (alprostadil), 952
Protamine sulfate, 858
Protease inhibitors
ABC transporters and, 105t, 106t
atazanavir, 1652–1653
darunavir, 1653–1654
distribution of, 25
efflux transporters and, 25
fosamprenavir, 1650–1651
for human immunodeficiency virus,
1644–1656
indinavir, 1654
lopinavir, 1651
polymorphisms and response to,
159t
for pulmonary disease, 1056
ritonavir, 1649–1650
and statins, interactions, 896
tipranavir, 1655–1656
Proteasome inhibitor, 1742–1743
Protein(s), plasma, distribution and, 24
Protein binding interaction, 77
Protein C, 853
deficiency of, 864
Protein kinase(s). See also Protein
tyrosine kinase inhibitors
classification of, 1731
Protein kinase C (PKC), inhibitors,
1012
Protein S, deficiency of, 864
Protein therapeutics
examples of, 5
history of, 5
production of, 5
Protein tyrosine kinase inhibitors
antitumor activity, mechanism of
action of, 1731–1732
resistance, mechanisms of,
1732–1733, 1733f
Prothrombin, activation, 852
Prothrombin factor V polymorphism,
161t
Prothrombin time (PT), shortened, 863
Proton pump inhibitors
adverse effects of, 1312
chemistry of, 1311–1312